NCT04839341View on ClinicalTrials.gov

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions
Relapsed/Refractory AML
Interventions
DRUG

Uproleselan

A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin

Trial Locations (2)

300020

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

Unknown

The First Affiliated Hospital of Zhejiang University, Hangzhou

Sponsors

Lead Sponsor

Apollomics Inc.
All Listed Sponsors
lead

Apollomics Inc.

INDUSTRY

NCT04839341 - Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients | Biotech Hunter | Biotech Hunter